ArticleOncotarget2017
Overexpression of RAD51B predicts a preferable prognosis for non-small cell lung cancer patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 26 citations in OpenAlex.
- Identification of a RAD51B enhancer variant for susceptibility and progression to glioma.Cancer cell international · 2023Article
- Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer.International journal of general medicine · 2022Article
- Article
- Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice.Genes & cancer · 2020Article
- Silencing of RAD51AP1 suppresses epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.Thoracic cancer · 2019Article
- Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development.Oncotarget · 2019Article
- Aberrant Expression of miR-362 Promotes Lung Cancer Metastasis through Downregulation of Sema3A.Journal of immunology research · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related death. The majority of patients are diagnosed at an incurable advanced stage with poor prognosis. A recent study associated the methylation of homologous recombination genes with expression of immune checkpoints in lung squamous cell carcinoma. However, the correlation between them remains unclear. In our study, we propose that RAD51B, a repair gene in the homologous recombination process, which is noticed to be a key player in the maintenance of chromosome integrity and in sensing DNA damage, can act as an independent factor affecting the prognosis of non-small-cell lung cancer (NSCLC). Univariate analysis showed that overexpression of RAD51B is statistically significant correlated with better prognosis (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.